Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia-Reference-Cited by-同舟云学术

Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia

Published:2025-11 Issue: Volume:289 Page:117-126
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Landmesser Ulf,Laufs Ulrich,Schatz Ulrike,Winzer Ephraim B.,Nowak Bernd,Kassner Ursula,Gouni-Berthold Ioanna,Esteban Alicia,Lubyayi Lawrence,Krueger Andre,Streich Jan Hendrik,Hentschke Christian,Achouba Assya,Banach Maciej

Funder

Novartis

Novartis Pharma

Publisher

Elsevier BV

Reference47 articles.

1. Deaths from cardiovascular disease surged 60% globally over the last 30 years: report—World Heart Federation 2024 [Available from: https://world-heart-federation.org/news/deaths-from-cardiovascular-disease-surged-60-globally-over-the-last-30-years-report/. [Accessed 11 June 2025].

2. Cardiovascular diseases (CVDs) 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)?gad_source=1&gclid=EAIaIQobChMIo7qlyMTBhwMVMaRmAh1HPzv2EAAYASAAEgKKEPD_BwE. [Accessed 11 June, 2025].

3. Global burden of cardiovascular D, risks C. Global burden of cardiovascular diseases and risks, 1990-2022;Mensah;J Am Coll Cardiol,2023

4. DE Bloom, et al. The Global economic Burden of noncommunicable diseases 2011. Available from WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf [Accessed 11 June 2025].

5. European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics;Timmis;Eur Heart J,2024